Pharmadrug Inc.
Other OTC•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.Company Description
- CEO
- Mr. Robert J. Steen
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Address
- 77 King Street West Toronto ON Canada M5K 1H1
- IPO Date
- May 19, 2017
- Website
- pharmadrug.ca
- Similar Companies
- Business
- Pharmadrug Inc. operates as a specialty pharmaceutical company. It focuses on the research, development, and commercialization of controlled-substances and natural medicines, such as psychedelics, cannabis, and naturally-derived approved drugs. It also imports and distributes medical cannabis to pharmacies in Germany and rest of the European Union; and owns and operates Super Smart, an entity building to elevate the use of functional mushrooms and psilocybin mushrooms. In addition, the company engages in the researching and reformulating established natural medicines. It has a research agreement with the University of Michigan to evaluate N, N-dimethyltryptamine's (DMT) potential role in normal, diseased, and altered states of consciousness, as well as an agreement with Southwest Research Institute for initiating non-clinical and clinical manufacturing of cepharanthine; and clinical trial agreement with Johns Hopkins University to conduct a clinical study comparing acute and enduring psychological and neural effects of DMT and an undisclosed potently active comparator molecule. The company was formerly known as Aura Health Inc. and changed its name to Pharmadrug Inc. in October 2019. The company is based in Toronto, Canada.
Company News
PharmaDrug Announces Resignation of Rob Steen as CEO and From Board of Directors
PharmaDrug Announces Strategic Review Process Intended to Maximize Shareholder Value
PharmaDrug Announces Issuance of Debenture Units
PharmaDrug Announces Proposed Issuance of Debenture Units
PharmaDrug's Sairiyo Therapeutics Announces Successful Completion of Stability Study of PD-001 (Patented Reformulated Cepharanthine) to Support Use in Phase 1 Study for Viral Infectious Diseases
PharmaDrug's Sairiyo Therapuetics Announces Initiation of Study Start-Up Activities and Design for Clinical Trial of PD-001 (Patented Reformulated Cepharanthine) for Viral Infectious Diseases
PharmaDrug's Sairiyo Therapuetics Provides Strategic Plans to Advance PD-001 (Patented Reformulated Cepharanthine) for Viral Infectious Diseases
PharmaDrug's Sairiyo Therapuetics Announces Independent Screening Identifying Cepharanthine's Potential to Bind to Monkeypox (Mpox) Proteins
PharmaDrug's Sairiyo Therapuetics Receives Approval to Initiate Phase 1 Clinical Trial of Patented Reformulated Cepharanthine
PharmaDrug's Sairiyo Therapeutics Submits Clinical Trial Application for Phase 1 Study of Patented Reformulated Cepharanthine
PharmaDrug Announces Director Appointment and Resignation
PharmaDrug's Sairiyo Therapeutics Completes Clinical and Regulatory Package for Phase 1 Study of Patented Reformulated Cepharanthine
PharmaDrug Appoints Current Board Member Dr. David Kideckel as Chairman
PharmaDrug's Sairiyo Therapeutics pursuing in-human study of PD-001 in Australia following manufacturing milestone
PharmaDrug's Sairiyo Successfully Demonstrates Ability to Manufacture Cepharanthine (PD-001) for Human Clinical Studies
PharmaDrug Inc. Engages Investor Relations and Marketing Service Providers
PharmaDrug Inc. Announces Successful Closing of Non-Brokered Private Placement
PharmaDrug Inc. Announces Proposed Non-Brokered Private Placement
PharmaDrug to continue Securedose Synthetics' R&D activities following acquisition
PharmaDrug Inc. Announces Grant of Stock Options